ESErnesto Silva

Ernesto Silva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ernesto Silva has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Anders Eklund

    Department of Medicine and CMM, Respiratory Medicine Unit, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden

    2 shared publications
  • Johan Grunewald

    Respiratory Medicine Division, Department of Medicine Solna, and Center for Molecular Medicine (CMM), Karolinska Institutet; and Respiratory Medicine, Theme Inflammation and Infection, Karolinska University Hospital, Stockholm, Sweden.

    2 shared publications
  • Ed Barker

    1 shared publication
  • Fariba Sabounchi-Schütt

    1 shared publication
  • Hanna Eriksson

    1 shared publication
  • Hanna Kjellin

    Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden ; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden ; Science for Life Laboratory, Cancer Proteomics Mass Spectrometry, Karolinska Institutet, Solna, Sweden

    1 shared publication

Latest Publications

    • 29 March 2016
      • Vol. 33  (1) , 17-28

    Alterations in the membrane-associated proteome fraction of alveolar macrophages in sarcoidosis.

    by Hanna Kjellin, Ernesto Silva, Rui Branca, Anders Eklund, Per-Johan Jakobsson, Johan Grunewald, Åsa M Wheelock

    Alveolar macrophages are implicated in the pathogenesis of lung sarcoidosis. Their interaction with T-cells leads to an inflammatory response that may either resolve within 2 years, or become chronic with an increased risk to develop lung fibrosis. To perform quantitative profiling of the membrane-associated proteome of alveolar macrophages in sarcoidosis patients and healthy individuals to identify specific proteins and pathways involved in sarcoidosis pathology. Differential proteomic analysis was performed on iTRAQ (isobaric Tag for Relative and Absolute Quantitation) labeled samples using tandem mass spectrometry. Subsequently, uni- and multivariate statistical analyses and pathway- and network analyses were performed. Eighty proteins were differentially expressed between healthy and sarcoidosis patients. Down-stream pathway analysis confirmed our recent reports of up-regulation of two phagocytotic pathways: Fcγ receptor-mediated phagocytosis and clathrin-mediated endocytosis signaling. An additional pathway, pyruvate metabolism, was found to be up-regulated in sarcoidosis patients. The oxidative phosphorylation pathway was differentially expressed in subgroups of sarcoidosis, with up-regulation in Löfgren's patients and down-regulation in non-Löfgren's patients. This unprecedented proteome profiling of the membrane-associated fraction of alveolar macrophages confirmed previous findings of alterations in phagocytotic pathways due to sarcoidosis, as well as indicated a differential dysregulation of the oxidative phosphorylation pathway related to disease outcome in sarcoidosis.


    • 1 March 2007
      • Vol. 24  (1) , 24-32

    A quantitative proteomic analysis of soluble bronchoalveolar fluid proteins from patients with sarcoidosis and chronic beryllium disease.

    by Ernesto Silva, Stephanie Bourin, Fariba Sabounchi-Schütt, Ylva Laurin, Ed Barker, Lee Newman, Hanna Eriksson, Anders Eklund, Johan Grunewald

    Sarcoidosis and chronic beryllium disease (CBD) are granulomatous disorders which can lead to development of chronic inflammation and fibrosis. These diseases have several similarities from their clinical aspects. The aim of this study was to compare the protein profile at the site of active inflammation i.e. the lungs of patients with sarcoidosis and CBD. Bronchoalveolar lavage (BAL) proteins from patients having sarcoidosis or CBD were studied using two dimensional gel based proteomics. In this study, we used Difference Gel Electrophoresis (DIGE) proteomics approach to analyse the protein expression profiles from sarcoidosis patients (n=4), CBD (n=4) and healthy controls (n = 5). Subsequently, differentially expressed proteins were identified by using mass spectrometry. We found 37 protein-spots with statistically different expression levels, and identified 14 of these proteins. The protein expression levels of peroxiredoxin 5, heat shock protein 70, complement C3, annexin A2 and transthyretin were significantly different in sarcoidosis versus control group. The proteins; hemopexin, beta2-microglobulin, alpha-1 antitrypsin, cystatin B, IgG kappa chain, apolipoprotein A1, and albumin were significantly different between CBD versus control group. When comparing CBD versus sarcoidosis, we found superoxide dismutase and hemoglobin upregulated in the CBD group. By using quantitative proteomics, we were able to find proteins with different expression levels in both diseases.